Join our community of smart investors

Astra in $6bn oncology deal

Tie-up with Japan’s Daiichi Sankyo follows on from an agreement between the pair last year
Astra in $6bn oncology deal

AstraZeneca (AZN) has signed a $6bn (£4.7bn) oncology deal with Japanese pharma group Daiichi Sankyo. The tie-up pertains to Daiichi’s antibody drug conjugate (ADC) ‘DS-1062’. ADCs are targeted therapies that can deliver chemotherapy to cancer cells.

IC TIP: Buy at 8647p

To continue reading...
OR
Register for free
Read 3 articles for free each month
Have an account? Sign in